News articles about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anika Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.185704966485 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Anika Therapeutics (NASDAQ ANIK) opened at $56.18 on Friday. Anika Therapeutics has a 12 month low of $41.64 and a 12 month high of $60.29. The stock has a market capitalization of $821.94, a price-to-earnings ratio of 26.50, a price-to-earnings-growth ratio of 3.40 and a beta of 1.44.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.05. The business had revenue of $27.18 million during the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. Anika Therapeutics’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.59 EPS. analysts expect that Anika Therapeutics will post 1.9 earnings per share for the current year.
A number of equities research analysts have issued reports on the company. Barrington Research reiterated a “buy” rating and issued a $57.00 price target on shares of Anika Therapeutics in a research note on Thursday, December 28th. BidaskClub upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th.
In other news, CEO Charles H. Sherwood sold 5,991 shares of the firm’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $60.04, for a total transaction of $359,699.64. Following the completion of the transaction, the chief executive officer now owns 158,297 shares in the company, valued at $9,504,151.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Charles H. Sherwood sold 22,228 shares of the firm’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $60.06, for a total value of $1,335,013.68. Following the transaction, the chief executive officer now owns 158,297 shares of the company’s stock, valued at approximately $9,507,317.82. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,762 shares of company stock valued at $2,178,445. Company insiders own 6.57% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Anika Therapeutics (NASDAQ:ANIK) Getting Somewhat Favorable Media Coverage, Accern Reports” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/12/anika-therapeutics-anik-receives-news-impact-rating-of-0-15.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.